20 results about "Kidney transplant" patented technology

The invention discloses an auxiliary diagnosis system for renal transplantation rejection and typing thereof based on a peripheral blood immune cell map. Comprising a peripheral blood single cell acquisition unit, a mass spectrum flow cytometry unit, an original data preprocessing unit, a data conversion and normalization processing unit, a peripheral blood immune cell grouping acquisition unit, a peripheral blood immune cell map construction unit, a feature vector acquisition unit, a rejection prediction unit and a rejection typing prediction unit. According to the invention, a kidney transplantation two-stage diagnosis architecture is created for the first time; rejection detection and typing identification are realized through classification of an independently trained random forest binary classifier, and different TCMR / ABMR immune mechanisms are accurately matched; the traditional biopsy limitation is broken through, an auxiliary diagnosis scheme with high precision, low damage, moderate cost and typing identification capability is provided for the kidney transplantation rejection, and the method has important significance on timely discovery of the rejection of a kidney transplantation patient and improvement of prognosis.

The present disclosure relates to crystalline forms of N-(l-(tert-butyl)-lH-pyrazol-4-yl)-2-( 4-((6-((methylsulfonyl)quinolin-4-yl)oxy)-3-methylphenyl)acetamide of formula (II) and crystalline forms of salts thereof. The compound of formula (II) is a RIPK2 inhibitor for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and more specifically for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease

Systems and methods for identifying risk of kidney graft failure in a subject are provided. An image of a graft biopsy is obtained, the image representing at least a subset of a plurality of morphological classes including a tissue compartment and inflammation class. The image is inputted into a trained model that identifies, as output, for each morphological class in at least the subset, corresponding objects in the image that fall within the morphological class. For each morphological class, corresponding digital features are generated comprising a first subset of individual feature scores obtained using the objects for the morphological class and a second subset of composite feature scores obtained by combining individual feature scores. Digital features for each morphological class are compared to a reference criterion, thus determining risk of kidney graft failure.

The invention relates to the technical field of biological medicine, in particular to application of 4-VPS in preparation of a kit for screening and / or diagnosing hypertensive kidney injury. According to the invention, a detection sample of 4-VPS is peripheral blood, and the sample is convenient to collect, minimally invasive and easy to popularize clinically; meanwhile, functional experiments prove that 4-VPS can directly induce kidney injury, early diagnosis of hypertensive nephropathy is achieved through 4-VPS, a patient can receive intervention treatment in the early stage of the disease, the disease is delayed or even prevented from developing into the end-stage nephropathy, the requirement of the patient for subsequent dialysis treatment or kidney transplantation is reduced, personal medical expenditure is reduced, and the treatment cost is reduced. Meanwhile, consumption of social medical resources is reduced, and remarkable economic benefits are achieved.

The invention discloses application of nintedanib in preparation of a medicine for treating plant migration and plant mineralization, and belongs to the technical field of biological medicine. The research shows that the nintedanib has the effects of reducing deposition of extracellular matrix of an allogeneic kidney transplantation model mouse, improving renal tubular atrophy, relieving mouse CD206 + macrophage infiltration and reducing rejection injury degree and immune infiltration degree of kidney grafts after being administered under the administration dosage without generating liver and kidney toxicity and intestinal side effects; the lesion process of mouse chronic transplanted kidney rejection is obviously slowed down, and the damage of excessively activated inflammatory cells to the transplanted kidney is reduced. The results show that nintedanib can delay the progress of chronic transplantation renal fibrosis.

Subject of the present invention is a method for the early diagnosis and / or early risk prediction and / or risk monitoring and / or severity prediction of reduced graft function in a kidney transplantation patient, comprising the steps of: determining the level of pro-enkephalin or a fragment thereof in a bodily fluid sample obtained from said patient; and correlating the level of the pro-enkephalin or fragment thereof in the sample with the diagnosis and / or risk and / or severity of a reduced graft function, wherein the reduced graft function is a reduced graft function (SGF) or delayed graft function (DGF) of the kidney.

The present invention provides, among other things, a method of prophylaxis for kidney rejection comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplant. In another aspect, the present invention provides, among other things, a method of improving a kidney transplant in a recipient, comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplantation at a therapeutically effective amount, wherein the improvement in the kidney transplant results in prolonged stability of the kidney transplant, survival of the recipient, and / or reduced rejection symptoms as compared to a control.

The invention features methods for the treatment of Alport syndrome using a polypeptide containing an extracellular ActRII variant, such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant. The polypeptide may include an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer. Treatment of Alport syndrome with a polypeptide described herein may reduce kidney inflammation, reduce kidney fibrosis, slow disease progression, and / or improve kidney function, which may reduce or delay the need for a kidney transplant or dialysis.

A mechanical kidney transplant may include four modules to interconnect and clean blood. Blood flowing through at least one of the modules flows through dialyzer fiber / tubes, while an area surrounding that fiber / tubes receives a flow of physiological resin gel of a design that will remove impurities from the blood. A subsystem of one or more sensors (a) detects and sets an alarm condition when the physiological resin gel is degraded and may need partial or full replacement, and / or (b) detects and sets an alarm condition if blood leakage has occurred within the module.

The present disclosure relates to RIPK2 inhibitors of the formulae (I) or (II) for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and, more specifically, for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease.

The present invention relates to methods of treating or preventing ischemia reperfusion injury (IRI) in a subject receiving a donor organ transplant, wherein the methods involve administration of a complement factor 2 (C2) inhibitor to the subject. The present invention also relates to methods of improving allograft function and also to methods of reducing the risk of allograft loss in a subject receiving a donor organ transplant, wherein the methods involve administration of a C2 inhibitor to the subject. Furthermore, the present invention relates to methods of treating or preventing delayed graft function (DGF) in a subject receiving a kidney transplant, wherein the methods involve administration of a C2 inhibitor to the subject. The C2 inhibitor may be empasiprubart.

The application discloses a kind of graft injury multi-index combined noninvasive detection kit, by optimized multiplex real-time fluorescent quantitative polymerase chain reaction technology, realize the quantitative detection of six categories with closely related DNA virus after transplantation Complications, the present application relates to the field of in vitro detection technology of clinical sample.The graft injury multi-index combined noninvasive detection kit, the present application first realizes the synchronous detection of BK virus, JC virus, B19 virus, CMV virus, adenovirus and six kinds of closely related viruses of circovirus (TTV) with graft injury.Test data see example 7, from the detection results of 100 clinical kidney transplant patients, it can be seen that the kit of the present application can simultaneously accurately detect the load level of six viruses, to provide comprehensive infection risk assessment for clinicians.Compared with the prior art single virus detection method, the present application avoids the cumbersome process of multiple sampling and detection, significantly improves the clinical work efficiency.

The present invention discloses an improved method for kidney preservation solution, belonging to the technical field of organ preservation solutions. The method comprises adding a ganoderma lucidum extract and an epimedium extract to HC-A solution. The ganoderma lucidum extract contains ganoderma lucidum polysaccharides and total ganoderma lucidum triterpenes, while the epimedium extract contains icariin and epimedin. The improved method of the present invention, which adds the ganoderma lucidum extract and the epimedium extract to the HC-A solution, can reduce ischemic damage during cryopreservation of isolated kidneys by protecting mitochondrial structure, increasing calpain activity, and inhibiting cell apoptosis, oxidative stress, and inflammatory reactions. This method improves the preservation effect of HC-A solution for isolated kidneys, prolongs their preservation time, and thus increases the survival rate of kidney transplantation. This method provides a clinical approach to finding a safe and effective method for preserving donor kidneys.

The present invention provides, among other things, a. method of prophylaxis for kidney rejection comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplant. In another aspect, the present invention provides, among other things, a method of improving a kidney transplant in a recipient, comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplantation at a therapeutically effective amount, wherein the improvement in the kidney transplant results in prolonged stability of the kidney transplant, survival of the recipient, and / or reduced rejection symptoms as compared to a control.

The invention relates to the technical field of medical rehabilitation instruments, in particular to kidney transplantation post-operation rehabilitation equipment based on an artificial intelligence technology, which comprises a base, a push rod, a control panel, a back support plate, a plurality of rollers, two lifting tables, a rotating plate, two stable seats, two support seats, two support sleeves and two lifting rods, the rotating plate is used for supporting movement of the chest of a patient, and the back supporting plate is used for providing limiting support for the back position corresponding to the kidney of the patient; a rehabilitation optimization system is arranged in the control panel and used for obtaining real-time forward inclination angle data of the patient and the actual walking distance of the patient, conducting correlation analysis, judging the physical power condition of the patient based on an AI physical power evaluation model and automatically generating an adaptive movement distance. The physical strength condition of the patient is judged by monitoring the forward leaning action when the patient walks, then a walking rehabilitation scheme is provided in a targeted mode, and the problems that when the patient gets out of bed walking training after the kidney transplantation operation, due to insufficient physical strength, the body leans forward, a wound is pulled, and a transplanted kidney area is pressed are effectively solved.

The present technology provides methods of reducing ischemia-reperfusion (IR) injury in a kidney to be transplanted comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and / or NADH to the kidney prior to surgical transplantation of the kidney into a subject. Additionally, the present technology provides methods of reducing ischemia-reperfusion (IR) injury to a transplanted kidney in a subject comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and / or NADH to the subject after transplantation of the kidney into the subject and also provides bioavailable nanoparticles comprising NAD+ and / or NADH for use in such methods.

The present invention relates to a composition for diagnosing chronic rejection after kidney transplantation, and more specifically, to a biomarker composition for diagnosing chronic rejection after kidney transplantation, containing VSIG4 protein as an active ingredient, a composition for diagnosis, a kit, and the like. By using the biomarker composition and the like according to the present invention, chronic rejection after kidney transplantation can be more effectively diagnosed, and further, a therapeutic drug for targeting chronic rejection after kidney transplantation can be developed.

The invention relates to the technical field of organ preservation equipment, in particular to a multifunctional organ perfusion preservation device for organ transplantation. A limiting cylinder; an electromagnetic heating coil; a lavage mechanism; and a conveying carrier mechanism. The kidney transplantation full-flow technology breakthrough is achieved through an innovative integrated framework, the kidney is rapidly cooled to the glass transition critical temperature through the liquid nitrogen rapid freezing technology, accurate and uniform rewarming of the kidney is achieved by means of an alternating magnetic field constructed by an electromagnetic heating coil, dynamic lavage is conducted by matching with a lavage device and simulating the human physiological environment, and the kidney transplantation effect is improved. The method has the advantages that metabolic waste in the kidney can be thoroughly removed, a metabolite analyzer can detect multiple key indexes in real time and accurately evaluate the activity of the kidney, functional modules work cooperatively, core links such as short-term preservation, rewarming activation, deep lavage and activity detection are seamlessly connected in the transportation process, the in-vitro effective preservation time of the kidney is greatly prolonged, and the service life of the kidney is prolonged. The transplanting success rate is obviously improved and the use effect is good.

The invention relates to the technical field of kidney transplantation, in particular to an edge kidney supply mechanical perfusion repair device which comprises a perfusion box body, a partition plate is arranged in the perfusion box body and divides the interior of the perfusion box body into a containing cavity and a pump body cavity, an ice block cavity is formed above the containing cavity, and a fixing assembly is arranged in the containing cavity. A lifting assembly used for adjusting the inclination angle of the fixing assembly is arranged at the bottom of the fixing assembly, a pump assembly is arranged in the pump body cavity and communicates with a connecting pipe, one end of the connecting pipe penetrates through the pump body cavity and extends into the containing cavity to communicate with the kidney body, and the connecting pipe is of a corrugated structure. A first ice bag and a second ice bag are fixedly connected to the inner side wall of the containing cavity and the partition plate correspondingly, and a plurality of spines are arranged on the sides, close to the fixing table, in the first ice bag and the second ice bag correspondingly. The lifting assembly is matched with the corrugated connecting pipe to discharge bubbles and crush ice blocks when the lifting assembly inclines, the problems that an existing device is frequent in temperature alarm, abnormal in pressure and flow speed and the like are solved, and stable perfusion repair of the marginal donor kidney is achieved.

This invention relates to the field of biomarkers and their applications, specifically to biomarkers for delayed recovery of transplanted kidney function after kidney transplantation and their applications. Using a combination of metabolomics methods and enzyme-linked immunosorbent assay (ELISA), analysis revealed that the expression of the differentially expressed metabolite 8-hydroxydeoxyguanosine (8-OHdG) was significantly increased in patients with end-stage chronic kidney disease after kidney transplantation. High expression may be related to the severity of pre-transplant chronic kidney disease. The serum 8-OHdG concentration one day after kidney transplantation has a certain diagnostic value for the occurrence of delayed recovery of kidney function (DGF). Serum 8-OHdG levels fluctuate considerably and are correlated with post-operative changes in kidney function, providing a reference for clinically seeking reliable biological indicators for early diagnosis of whether DGF has occurred in kidney transplant patients, and aiding in the clinical evaluation of donor kidney quality and guiding subsequent treatment for patients.